Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 6, 2010, Pages 1005-1012

  Egerton, Nancy ^a  

^a Pharmacy Services   (United States)

Author keywords

Advanced; Breast cancer; Epothilones; Ixabepilone; Metastatic; Treatment schedules

Indexed keywords

AMPRENAVIR; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CARBAMAZEPINE; DELAVIRDINE; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INDINAVIR; ITRACONAZOLE; IXABEPILONE; KETOCONAZOLE; LAPATINIB; NELFINAVIR; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PROGESTERONE RECEPTOR; RIFAMPICIN; RITONAVIR; TAU PROTEIN; TAXANE DERIVATIVE; TRASTUZUMAB; VORICONAZOLE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BLOOD DISEASE; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; METASTASIS; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; NONHUMAN; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SHORT SURVEY; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EPOTHILONES; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; PERIPHERAL NERVOUS SYSTEM DISEASES; QUINAZOLINES; TREATMENT FAILURE; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 78149407714     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1467-x     Document Type: Short Survey

References (34)

1. K Gerth N Bedorf G Hofle H Irschik H Reichenbach 1996 Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties J Antibiot (Tokyo) 49 6 560 563 1:CAS:528:DyaK28XjvFSgsr8%3D (Pubitemid 26235665)
2. DM Bollag PA McQueney J Zhu O Hensens L Koupal J Liesch, et al. 1995 Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action Cancer Res 55 11 2325 2333 1:CAS:528:DyaK2MXlvFeqsr0%3D 7757983
3. FY Lee R Borzilleri CR Fairchild A Kamath R Smykla R Kramer, et al. 2008 Preclinical discovery of ixabepilone, a highly active antineoplastic agent Cancer Chemother Pharmacol 63 1 157 166 1:CAS:528:DC%2BD1cXhtF2kur%2FM 10.1007/s00280-008-0724-8 18347795
4. P Giannakakou R Gussio R Nogales KH Downing D Zaharevitz B Bollbuck, et al. 2000 A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells Proc Natl Acad Sci 97 6 2904 2909 1:CAS:528:DC%2BD3cXitVahtrk%3D 10.1073/pnas.040546297 10688884 (Pubitemid 30159270)
5. MA Jordan 2002 Mechanism of action of antitumor drugs that interact with microtubules and tubulin Curr Med Chem Anticancer Agents 2 1 1 17 1:CAS:528:DC%2BD38XislGmurg%3D 10.2174/1568011023354290 12678749
6. M Wartmann KH Altmann 2002 The biology and medicinal chemistry of epothilones Curr Med Chem Anticancer Agents 2 1 123 148 1:CAS:528: DC%2BD38XislGmu78%3D 10.2174/1568011023354489 12678754 (Pubitemid 34649871)
7. C Dumontet MA Jordan FF Lee 2009 Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies Mol Cancer Ther 8 1 17 25 1:CAS:528:DC%2BD1MXjvFSmtA%3D%3D 10.1158/1535-7163.MCT-08-0986 19139109
8. E Rivera J Lee A Davies 2008 Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors Oncologist 13 12 1207 1223 1:CAS:528:DC%2BD1MXhvV2nurw%3D 10.1634/theoncologist.2008-0143 19088324
9. LB Michaud 2009 The epothilones: how pharmacology relates to clinical utility Ann Pharmacother 43 7 1294 1309 1:CAS:528:DC%2BD1MXhtVWjt7vM 10.1345/aph.1M005 19584389
10. ® (ixabepilone) prescribing information. Bristol-Myers Squibb Company, Princeton, NJ
11. FY Lee A Camuso S Castaneda K Fager C Flefleh I Inigo, et al. 2006 Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and -resistant tumor types Proc Am Assoc Cancer Res 47 119 (Abstr 503)
12. S Goodin MP Kane EH Rubin 2004 Epothilones: mechanism of action and biologic activity J Clin Oncol 22 10 2015 2025 1:CAS:528:DC%2BD2cXptlCks7w%3D 10.1200/JCO.2004.12.001 15143095 (Pubitemid 41095195)
13. S Mani H McDaid A Hamilton H Hochster MB Cohen D Khabelle, et al. 2004 Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors Clin Cancer Res 10 4 1289 1298 1:CAS:528:DC%2BD2cXhsVCqur0%3D 10.1158/1078-0432.CCR-0919-03 14977827 (Pubitemid 38365219)
14. SH Zhuang M Agrawal M Edgerly S Bakke H Kotz P Thambi, et al. 2005 A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days Cancer 103 9 1932 1938 1:CAS:528:DC%2BD2MXktFGntrw%3D 10.1002/cncr.20977 15800893 (Pubitemid 40563267)
15. A Awada MJ Piccart SF Jones RA Peck T Gil D Lebwohl, et al. 2009 Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard chemotherapy Cancer Chemother Pharmacol 63 3 417 425 1:CAS:528:DC%2BD1cXhsFejtrrE 10.1007/s00280-008-0751-5 18446338
16. EA Perez G Lerzo X Pivot E Thomas L Vahdat L Bosserman, et al. 2007 Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 23 3407 3414 1:CAS:528:DC%2BD2sXhtVajsb%2FP 10.1200/JCO.2006.09.3849 17606974 (Pubitemid 47310876)
17. E Thomas J Tabernero M Fornier P Conte P Fumoleau A Lluch, et al. 2007 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 23 3399 3406 1:CAS:528:DC%2BD2sXhtVajsb%2FN 10.1200/JCO.2006.08.9102 17606975 (Pubitemid 47310875)
18. H Roche L Yelle F Cognetti L Mauriac C Bunnell J Sparano, et al. 2007 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy J Clin Oncol 25 23 3415 3420 1:CAS:528:DC%2BD2sXhtVajsb%2FK 10.1200/JCO.2006.09.7535 17606972 (Pubitemid 47310877)
19. N Denduluri JA Low JJ Lee AW Berman JM Walshe U Vatas, et al. 2007 Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes J Clin Oncol 25 23 3421 3427 1:CAS:528:DC%2BD2sXhtVajsb%2FE 10.1200/JCO.2006.10.0784 17606971 (Pubitemid 47310878)
20. JA Low SB Wedam JJ Lee AW Berman A Brufsky SX Yang, et al. 2005 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer J Clin Oncol 23 12 2726 2734 1:CAS:528:DC%2BD2MXktleqtro%3D 10.1200/JCO.2005.10.024 15837987 (Pubitemid 46179462)
21. N Denduluri JJ Lee J Walshe AW Berman U Vatas CK Chow, et al. 2007 Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer Invest New Drugs 25 1 63 67 1:CAS:528:DC%2BD28XhtFegtrfN 10.1007/s10637-006-9006-7 16933153 (Pubitemid 44657644)
22. JW Smith SJ Vukelja AC Rabe RE Pluenneke N Wentworth-Hartung LB Benaderet, et al. 2009 Preliminary toxicity results of a phase II randomized trial of weekly or every-3-week ixabepilone in metastatic breast cancer (MBC) Cancer Res 69 24 Suppl 856s (Abstr 6099)
23. FY Lee A Camuso S Castenada C Flefleh I Ingio D Kan, et al. 2006 Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts J Clin Oncol 24 18S 597s (Abstr 12017)
24. C Bunnell L Vahdat L Schwartzberg J Gralow J Klimovsky V Poulart, et al. 2008 Phase I/II study of ixabepilone plus capecitabine in anthracycline- pretreated/resistant and taxane-resistant metastatic breast cancer Clin Breast Cancer 8 3 234 241 1:CAS:528:DC%2BD1cXovFCiu7g%3D 10.3816/CBC.2008.n.026 18650153 (Pubitemid 351962144)
25. ES Thomas HL Gomez RK Li HC Chung LE Fein VF Chan, et al. 2007 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 33 5210 5217 1:CAS:528:DC%2BD2sXhsVKnsbzO 10.1200/JCO.2007.12.6557 17968020 (Pubitemid 350232252)
26. Hortobagyi GN, Perez EA, Vrdoljak E, Medina C, Xu B, Conte P et al (2008) Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials. Presented at the American society of clinical oncology breast cancer symposium, Washington, DC, 5-7 Sept (Abstr 186)
27. J O'Shaughnessy D Miles S Vukelja V Moiseyenko JP Ayoub G Cervantes, et al. 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 12 2812 2823 10.1200/JCO.2002.09.002 12065558 (Pubitemid 34651510)
28. Orsini L, Mukhopadhyay P, Peck R, Corey-Lisle P (2009) Quality adjusted time without symptoms or toxicities (Q-TWiST) of ixabepilone plus capecitabine versus capecitabine for metastatic breast cancer (MBC). Presented at the American society of clinical oncology breast cancer symposium, Orlando, FL, May 29-June 2 (Abstr 170)
29. Orsini L, Mukhopadhyay P, Peck R, Corey-Lisle P (2009) Quality adjusted time without symptoms or toxicities (Q-TWiST) of ixabepilone (Ixa) plus capecitabine (cape) versus capecitabine for metastatic breast cancer (MBC) patients with poor prognostic features (PPF). Cancer Res 69:782s (Abstr 5051)
30. FY Lee KL Covello S Castaneda DR Hawken D Kan A Lewin, et al. 2008 Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models Clin Cancer Res 14 24 8123 8131 1:CAS:528:DC%2BD1cXhsV2it7vN 10.1158/1078-0432.CCR-08-0025 19088027
31. HS Rugo M Campone D Amadori A Wardley A Villa PF Conte, et al. 2009 Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC) J Clin Oncol 27 15S 47s (Abstr 1029)
32. PN Mainwaring T Nguyen G Price D Venter 2009 Ixabepilone and lapatinib for HER2-positive advanced breast cancer: preclinical rationale and phase I trial J Clin Oncol 27 15S 128s (Abstr 2582)
33. J Baselga M Zambetti A Llombart-Cussac G Manikhas E Kubista GG Steger, et al. 2009 Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer J Clin Oncol 27 4 526 534 1:CAS:528:DC%2BD1MXivFyjur4%3D 10.1200/JCO.2007.14.2646 19075286
34. CE Horak FY Lee L Xu S Galbraith J Baselga, et al. 2009 High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: a retrospective analysis J Clin Oncol 27 15S 167s (Abstr 3587)